BMC Cancer

期刊名称 BMC Cancer 

期刊缩写 BMC CANCER   
学科分类 医学、生命科学 

出版周期 不定期   
审稿速度 6.85 个月 （平均） 

投稿命中率 38.12 % （均值)   
期刊主页 http://www.biomedcentral.com/1471-2407/   
ISSN 号 1471-2407   
IF 趋势     2005     2006     2007    2008     2009     2010     2011     2012   
               1.992     2.359    2.709   3.087    2.736     3.153    3.011    3.333   
被收录情况 1. Science Citation Index Expanded 
                  2. Current Contents - Clinical Medicine   
PubSci评语 该刊是开放期刊，必须需要交纳Open Access费用2090美元。评审很专业 要求比较细致 对语言的要求不是非常高 审稿专家会对相应语言问题提出修改意见 但是审稿速度比较慢 一审3到6个月 通常要三审才能接受 接受后很快可以在线发表 投稿到发表一个是11个月 一个9个月 开放杂志 容易被相关研究者关注 同时也意味着作者要交不少的费用。   
期刊简介 BMC Cancer是一个开发的同行评审期刊，出版关于癌症研究的所有研究成果，包括癌症的病理生理学、预防、诊断和治疗。同时，该刊对分子和细胞生物学、遗传学、流行病学及临床试验也持欢迎态度。   
投稿注意事项 特别提醒：BMC Cancer是一个开发获取类期刊，接受发表的论文需要交纳Open Access费用1290英镑或2090美元或1545欧元。低收入国家的作者可以获得减免。
一般注意事项：
About BMC Cancer
Aims and scope | Editorial team | Open access | Article-processing charges |Indexing services | Publication and peer review process | Editorial policies |Citing articles in BMC Cancer | Why publish your article in BMC Cancer?
This page includes information about the aims and scope of BMC Cancer, editorial policies, open access and article-processing charges, the peer review process and other information. For details of how to prepare and submit a manuscript through the online submission system, please see the instructions for authors.
Scope
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.
It is journal policy to publish work deemed by peer reviewers to be a coherent and sound addition to scientific knowledge and to put less emphasis on interest levels, provided that the research constitutes a useful contribution to the field.
Editorial team
Executive Editor
Dafne Solera
Editorial Board Manager
Paul Lambert
Journal Development Manager
Genevieve Horne
Senior Managing Editor
Diana Marshall
Publisher
Jo Appleford-Cook
Open access
All articles published by BMC Cancer are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
Authors of articles published in BMC Cancer are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the BioMed Central copyright and license agreement.
For authors who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Article-processing charges
Open access publishing is not without costs. BMC Cancer therefore levies an article-processing charge of £1290/$2090/€1545 for each article accepted for publication. We routinely waive charges for authors from low-income countries. Generally, if the submitting author's institution is a Member the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. For further details, see our article-processing charge page.
Indexing services
All articles published in BMC Cancer are included in PubMed, the most widely used biomedical bibliographic database service, which is run by the US National Library of Medicine. Other bibliographic databases that index articles published in BMC Cancer include:
CABI
CAS
Cases Database
Citebase
Current contents
DOAJ
Embase
Global Health
Google Scholar
Index Copernicus
MEDLINE
OAIster
PubMed
PubMed Central
Science Citation Index Expanded
SCImago
Scirus
Scopus
SOCOLAR
Zetoc

The full text of all research articles is deposited in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and other digital archives includinge-Depot (The Netherlands). All case reports published in this journal will also be indexed inCases Database.
BMC Cancer is tracked by Thomson Reuters (ISI) and has an Impact Factor of 3.33.
Publication and peer review process
Publication of research articles by BMC Cancer is dependent primarily on their scientific validity and coherence as judged by our external expert editors and/or peer reviewers, who will also assess whether the writing is comprehensible and whether the work represents a useful contribution to the field.
BMC Cancer operates an 'open peer review' policy meaning reviewers are asked to sign their reviews. The pre-publication history including all submitted versions, reviewers' reports and authors' responses will be linked to from the published article.
Authors will be able to check the progress of their manuscript through the submission system at any time by logging into My BMC Cancer, a personalized section of the site.
Reprints
High-quality, bound reprints can be purchased for all articles published. Please see ourreprints website for further information about ordering reprints.
Supplements
BMC Cancer will consider supplements based on proceedings (full articles or meeting abstracts), reviews or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print. All full length articles (proceedings, reviews or research articles) are indexed by PubMed. PubMed displays the title of the supplement only in the case of meeting abstract collections. For further information, please contact us.
Editorial policies
All manuscripts submitted to BMC Cancer should adhere to BioMed Central's editorial policies.
Appeals and complaints
Authors who wish to appeal a rejection or make a complaint should, in the first instance, contact the Executive Editor who will provide details of the journal's complaints procedure.
Citing articles in BMC Cancer
Articles in BMC Cancer should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. BMC Cancer [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. BMC Cancer 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Why publish your article in BMC Cancer?
High visibility
BMC Cancer's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results.
Speed of publication
BMC Cancer offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles are published with their final citation immediately upon acceptance in a provisional PDF form. The article will subsequently be published in both fully browsable web form, and as a formatted PDF; the article will then be available through BMC Cancer, BioMed Central and PubMed Central and will also be included in PubMed.
Flexibility
Online publication in BMC Cancer gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in BMC Cancer are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on BMC Cancer's pages and on the BioMed Central homepage.
In addition, articles published in BMC Cancer may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in BMC Cancer. A list of articles recently press-released by journals published by BioMed Central is available here.
Copyright
Authors of articles published in BMC Cancer retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the BioMed Central copyright and license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.   
编辑部信息 所在地：  国家 意大利   
  Section Editors
Paolo Bruzzi National Cancer Research Institute, Italy
Carlos Caldas Cambridge Research Institute, UK
Ian Cree Warwick Medical School, Coventry, UK
Shoukat Dedhar British Columbia Cancer Agency, Canada
John A Hartley University College London, UK
Manami Inoue University of Tokyo, Japan
Mark McKeage University of Auckland, New Zealand
Christophe Nicot Kansas University Medical Center, USA
Stephen P Povoski The Ohio State University, USA
Dirk Vordermark Martin Luther University Halle-Wittenberg, Germany
Deputy Section Editors
Andrzej K Bednarek Medical University of Lodz, Poland
Ian Chau Royal Marsden Hospital, UK
Stephen Clarke University of Sydney, Australia
Nathan C Hall The Ohio State University, USA 

网友投稿经验整理：
1月6号投，2月11日under review, 3月17Editorial discussion至今，写催稿信N次，就是不给first decision,慢的够可以啊，建议大家着急毕业千万别投
贡献者： Pearl
是很慢，但修了两次后终于是最后改格式了。现在总共花了9个月的时间了。我没有催过他们，随他们怎么弄，只要能发表
贡献者：fangwy
分享体会： 
我们的文章是2009年2月投给该杂志的，直到2009年6月才通知需要某些研究批文。2009年10月份小修，2010年2月大修。直到我们连续发邮件询问，2010年8月20日被拒，所以楼上的同仁们是非常幸运了，所以IF也在下降，所以。。。
贡献者：体会
如果希望你的稿子能看沧海成桑田，那就投这一家吧，急三火四的就不要离这家杂志远一点，那个慢啊，投了两个多月了还只是submitted的状态，连外审也没送呢，如果你催，编辑会在十天后回复，说你的稿子他的同事正在积极做送审前的处理，估计是需要把稿子里的字母一个个都读上个几W次吧，不然肯定用不了那久的
贡献者：60.16.168.63
研究方向：肿瘤影像      审稿时间:约6个月         
投两篇全中 感觉对稿件没有歧视 评审很专业 要求比较细致 对语言的要求不是非常高 审稿专家会对相应语言问题提出修改意见 但是审稿速度比较慢 一审3到6个月 通常要三审才能接受 接受后很快可以在线发表 投稿到发表一个是11个月 一个9个月 开放杂志 容易被相关研究者关注 同时也意味着作者要交不少的费用 在投稿时就有说明 前面有作者不交钱还在这里炫耀 丢人丢到国外去了 如果都像你这样 人家对中国的投稿者会是什么样的看法呢 没有诚信 用自掘坟墓不为过
贡献者：202.209.187.131
研究方向：肿瘤 临床     审稿时间:约12个月    接收率：约25%     
我都投稿6个多月了，几乎每个月催稿1-2次，一会说找不到相关审稿人，一会说需要讨论。发回改稿还要大修，小修，非得按照他们的标准，还不知道中不中……纠结呀，不知道该不该撤稿，看了以上的评论……
贡献者：
研究方向：肿瘤研究 基础     审稿时间:约1个月    接收率：约25%     
是的，这个杂志还可以了。3分多的专业的肿瘤杂志！很好了!只要你设计规范、该做的实验都做了，可以投，那样速度就很快了，哥中了一篇，从投到发4个月，没有补实验，该做的实验都做了。
贡献者：116.6.21.98
审稿时间:约24个月    接收率：约5%     SCI(2010)：3.153 
不错，3分多的杂志，很好了，不过这个杂志要求严格，功能试验要求完整。最主要是不适合靠这个杂志毕业。 
审稿要1年，且很可能在你大修、小修后（花费1年多），花费1年多把你给拒稿，那就吐血了，这个比例相当高。 
原来以为这个杂志好投，都投稿，结果都被弄了1年拒稿，揪心呀。
贡献者：116.6.21.98